133 related articles for article (PubMed ID: 38771994)
41. Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany.
Huebner H; Kurbacher CM; Kuesters G; Hartkopf AD; Lux MP; Huober J; Volz B; Taran FA; Overkamp F; Tesch H; Häberle L; Lüftner D; Wallwiener M; Müller V; Beckmann MW; Belleville E; Ruebner M; Untch M; Fasching PA; Janni W; Fehm TN; Kolberg HC; Wallwiener D; Brucker SY; Schneeweiss A; Ettl J
BMC Cancer; 2020 Nov; 20(1):1091. PubMed ID: 33176725
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of Population-Level Changes Associated With the 2021 US Preventive Services Task Force Lung Cancer Screening Recommendations in Community-Based Health Care Systems.
Ritzwoller DP; Meza R; Carroll NM; Blum-Barnett E; Burnett-Hartman AN; Greenlee RT; Honda SA; Neslund-Dudas C; Rendle KA; Vachani A
JAMA Netw Open; 2021 Oct; 4(10):e2128176. PubMed ID: 34636916
[TBL] [Abstract][Full Text] [Related]
43. Does socioeconomic status account for racial and ethnic disparities in childhood cancer survival?
Kehm RD; Spector LG; Poynter JN; Vock DM; Altekruse SF; Osypuk TL
Cancer; 2018 Oct; 124(20):4090-4097. PubMed ID: 30125340
[TBL] [Abstract][Full Text] [Related]
44. Clinical Characteristics and Prognosis of Patients With Advanced Non-Small-cell Lung Cancer Who Are Ineligible for Clinical Trials.
Kawachi H; Fujimoto D; Morimoto T; Ito M; Teraoka S; Sato Y; Nagata K; Nakagawa A; Otsuka K; Tomii K
Clin Lung Cancer; 2018 Sep; 19(5):e721-e734. PubMed ID: 29934133
[TBL] [Abstract][Full Text] [Related]
45. Pancreatic Cancer Clinical Treatment Trials Accrual: A Closer Look at Participation Rates.
Guerra CE; Kelly S; Redlinger C; Hernández P; Glanz K
Am J Clin Oncol; 2021 Jun; 44(6):227-231. PubMed ID: 33710138
[TBL] [Abstract][Full Text] [Related]
46. Survival of Patients With Advanced or Metastatic Renal Cell Carcinoma in Routine Practice Differs From That in Clinical Trials-Analyses From the German Clinical RCC Registry.
Marschner N; Staehler M; Müller L; Nusch A; Harde J; Koska M; Jänicke M; Goebell PJ;
Clin Genitourin Cancer; 2017 Apr; 15(2):e209-e215. PubMed ID: 27720164
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of Revised US Preventive Services Task Force Lung Cancer Screening Guideline Among Women and Racial/Ethnic Minority Populations.
Reese TJ; Schlechter CR; Potter LN; Kawamoto K; Del Fiol G; Lam CY; Wetter DW
JAMA Netw Open; 2021 Jan; 4(1):e2033769. PubMed ID: 33433600
[TBL] [Abstract][Full Text] [Related]
48. Eligibility criteria in randomized phase II and III adjuvant and neoadjuvant breast cancer trials: not a significant barrier to enrollment.
Filion M; Forget G; Brochu O; Provencher L; Desbiens C; Doyle C; Poirier B; DuRocher M; Camden S; Lemieux J
Clin Trials; 2012 Oct; 9(5):652-9. PubMed ID: 23060323
[TBL] [Abstract][Full Text] [Related]
49. Clinical Trials Eligibility of Patients With Malignant Pleural Mesothelioma: Use of Novel Therapies and Outcomes.
Lau B; Boyer M; Lee JH; Kao S
Clin Lung Cancer; 2020 Jul; 21(4):378-383.e1. PubMed ID: 32249197
[TBL] [Abstract][Full Text] [Related]
50. Using Real-World Data to Rationalize Clinical Trials Eligibility Criteria Design: A Case Study of Alzheimer's Disease Trials.
Li Q; Guo Y; He Z; Zhang H; George TJ; Bian J
AMIA Annu Symp Proc; 2020; 2020():717-726. PubMed ID: 33936446
[TBL] [Abstract][Full Text] [Related]
51. Geographic Distribution and Survival Outcomes for Rural Patients With Cancer Treated in Clinical Trials.
Unger JM; Moseley A; Symington B; Chavez-MacGregor M; Ramsey SD; Hershman DL
JAMA Netw Open; 2018 Aug; 1(4):e181235. PubMed ID: 30646114
[TBL] [Abstract][Full Text] [Related]
52. Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials.
Duma N; Kothadia SM; Azam TU; Yadav S; Paludo J; Vera Aguilera J; Gonzalez Velez M; Halfdanarson TR; Molina JR; Hubbard JM; Go RS; Mansfield AS; Adjei AA
Oncologist; 2019 Jan; 24(1):96-102. PubMed ID: 30413668
[TBL] [Abstract][Full Text] [Related]
53. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.
Heng DY; Choueiri TK; Rini BI; Lee J; Yuasa T; Pal SK; Srinivas S; Bjarnason GA; Knox JJ; Mackenzie M; Vaishampayan UN; Tan MH; Rha SY; Donskov F; Agarwal N; Kollmannsberger C; North S; Wood LA
Ann Oncol; 2014 Jan; 25(1):149-54. PubMed ID: 24356626
[TBL] [Abstract][Full Text] [Related]
54. Feasibility platform for stroke studies: an online tool to improve eligibility criteria for clinical trials.
Minnerup J; Trinczek B; Storck M; Hohenberger M; Wilpsbäumer S; Abdul-Rahim AH; Liesirova KT; Broeg-Morvay A; Meisterernst J; Lees KR; Mattle HP; Wersching H; Dziewas R; Schäbitz WR; Schilling M
Stroke; 2015 Jan; 46(1):137-42. PubMed ID: 25395412
[TBL] [Abstract][Full Text] [Related]
55. Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
Fung AS; Tam VC; Meyers DE; Sim HW; Knox JJ; Zaborska V; Davies J; Ko YJ; Batuyong E; Samawi H; Cheung WY; Lee-Ying R
Cancer Med; 2020 Jul; 9(13):4640-4647. PubMed ID: 32378799
[TBL] [Abstract][Full Text] [Related]
56. Eligibility for Endovascular Trial Enrollment in the 6- to 24-Hour Time Window: Analysis of a Single Comprehensive Stroke Center.
Jadhav AP; Desai SM; Kenmuir CL; Rocha M; Starr MT; Molyneaux BJ; Gross BA; Jankowitz BT; Jovin TG
Stroke; 2018 Apr; 49(4):1015-1017. PubMed ID: 29581344
[TBL] [Abstract][Full Text] [Related]
57. Use of implantable cardioverter defibrillators for primary prevention in the community: do women and men equally meet trial enrollment criteria?
Daugherty SL; Peterson PN; Wang Y; Curtis JP; Heidenreich PA; Lindenfeld J; Vidaillet HJ; Masoudi FA;
Am Heart J; 2009 Aug; 158(2):224-9. PubMed ID: 19619698
[TBL] [Abstract][Full Text] [Related]
58. Association of Dual Eligibility for Medicare and Medicaid With Heart Failure Quality and Outcomes Among Get With The Guidelines-Heart Failure Hospitals.
Bahiru E; Ziaeian B; Moucheraud C; Agarwal A; Xu H; Matsouaka RA; DeVore AD; Heidenreich PA; Allen LA; Yancy CW; Fonarow GC
JAMA Cardiol; 2021 Jul; 6(7):791-800. PubMed ID: 33825802
[TBL] [Abstract][Full Text] [Related]
59. Effect of Reasons for Screen Failure on Subsequent Treatment Outcomes in Cancer Patients Assessed for Clinical Trials.
Tiu C; Loh Z; Gan CL; Gan H; John T; Hawkes E
Oncology; 2019; 97(5):270-276. PubMed ID: 31266008
[TBL] [Abstract][Full Text] [Related]
60. A New Approach to Simplifying and Harmonizing Cancer Clinical Trials-Standardizing Eligibility Criteria.
Gerber DE; Singh H; Larkins E; Ferris A; Forde PM; Selig W; Basu Roy U
JAMA Oncol; 2022 Sep; 8(9):1333-1339. PubMed ID: 35925576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
